OptiNose (OPTN) Q3 2024 earnings summary

Executive summary

• XHANCE net revenue for Q3 2024 was $20.4 million, up 3% year-over-year, but below expectations due to slower uptake and inventory stocking effects.

• XHANCE received FDA approval for chronic sinusitis (chronic rhinosinusitis without nasal polyps), expanding its market opportunity and creating a significant near-term growth opportunity.

• Recent inflection in new prescription growth attributed to improved sales execution, enhanced payer access, and optimized prescription fulfillment, though overall demand growth has been slower than anticipated.

• Full-year 2024 net revenue guidance for XHANCE is reduced to $75–$79 million from prior $85–$90 million, implying 6–11% growth over 2023.

• Substantial doubt exists about the company's ability to continue as a going concern due to debt covenant risks and ongoing losses.

Financial highlights

• Q3 2024 XHANCE net revenue: $20.4 million, up from $19.8 million in Q3 2023; nine-month net revenue: $55.8 million, up 9% year-over-year.

• Average net revenue per prescription in Q3 2024: $320, a 36% increase year-over-year; year-to-date average: $285.

• SG&A plus R&D expenses for Q3 2024: $20.4 million, up $1 million year-over-year; year-to-date: $67.2 million, up $2 million.

• Net income for Q3 2024 was $0.5 million, compared to a net loss of $9.3 million in Q3 2023; nine-month net loss: $21.2 million.

• Cash and cash equivalents as of September 30, 2024: $82.5 million.

Outlook and guidance

• 2024 XHANCE net revenue guidance: $75–$79 million, down from $85–$90 million previously.

• 2024 average net revenue per prescription expected at $270, up from previous guidance of at least $250.

• 2024 operating expense guidance lowered to $90–$93 million (including $6 million stock-based compensation), down from $95–$101 million.

• Q4 2024 implied revenue guidance: $19–$23 million, reflecting uncertainty in demand growth and refill timing.

• No 2025 profitability guidance provided as management reevaluates projections in light of recent demand trends.